Department of Error (DOI:10.1016/S0140-6736(06)68891-0);Osteoporosis

Lancet

Volumn 367, Issue 9527, 2006, Pages 2010-2018

  Sambrook, Philip ^a   Cooper, Cyrus ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; ALKALINE PHOSPHATASE; ARZOXIFENE; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCITRIOL; CALCIUM; COLECALCIFEROL; ESTROGEN; ETIDRONIC ACID; GESTAGEN; GLUCOCORTICOID; IBANDRONIC ACID; LASOFOXIFENE; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE[1-34]; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM RANELATE; TELOPEPTIDE; VITAMIN D;

ALCOHOLISM; ALGORITHM; BIOCHEMISTRY; BODY WEIGHT; BONE DENSITOMETRY; BONE DENSITY; BONE FRAGILITY; BONE GROWTH; BONE MASS; BONE MINERALIZATION; BONE RADIOGRAPHY; BONE REMODELING; BONE STRENGTH; BONE TURNOVER; BREAST CANCER; CARDIOVASCULAR DISEASE; CIGARETTE SMOKING; CLINICAL ASSESSMENT; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG POTENTIATION; ESTROGEN DEFICIENCY; FALLING; FAMILY HISTORY; FOREARM FRACTURE; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HIP FRACTURE; HORMONAL THERAPY; HORMONE ACTION; HOT FLUSH; HUMAN; MEDICAL DECISION MAKING; MORTALITY; OCCUPATIONAL HAZARD; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PATHOPHYSIOLOGY; PHYSIOLOGY; POSTMENOPAUSE; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; RISK ASSESSMENT; RISK FACTOR; STROKE; TREATMENT DURATION; UPPER GASTROINTESTINAL TRACT; VEIN THROMBOSIS; VERTEBRA FRACTURE; WRIST FRACTURE;

EID: 33744992495     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(06)68966-6     Document Type: Erratum

References (98)

1. Cummings S., and Melton L. Epidemiology and outcomes of osteoporotic fractures. Lancet 359 (2002) 1761-1767
2. Melton L., and Cooper C. Magnitude and impact of osteoporosis and fractures. In: Marcus R., Feldman D., and Kelsey J. (Eds). Osteoporosis. 2nd edn. (2001), Academic Press, San Diego 557-567
3. Department of Health and Human Services. Bone health and osteoporosis: a report of the Surgeon-General (2004), US Department of Health and Human Services, Office of the Surgeon General, Rockville
4. Van Staa T., Dennison E., Leufkens H., and Cooper C. Epidemiology of fractures in England and Wales. Bone 29 (2001) 517-522
5. Kanis J., Johnell O., De Laet C., et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone 35 (2004) 375-382
6. Johnell O. The socioeconomic burden of fractures: today and in the 21st century. Am J Med 103 (1997) 20S-226
7. The EPOS Study Group. Incidence of vertebral fracture in Europe: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res 17 (2002) 716-724
8. Cooper C., Atkinson E., O'Fallon W., and Melton L. Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985-1989. J Bone Miner Res 7 (1992) 221-227
9. Ross P., Davis J., Epstein R., and Wasnich R. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 114 (1991) 919-923
10. Klotzbuecher C., Ross P., Landsman P., Abbott T., and Berger M. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15 (2000) 721-739
11. Melton L., Atkinson E., Cooper C., O'Fallon W., and Riggs B. Vertebral fractures predict subsequent fractures. Osteoporos Int 10 (1999) 214-221
12. Center J., Nguyen T., Schneider D., Sambrook P., and Eisman J. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353 (1999) 878-882
13. Heaney R. Remodeling and skeletal fragility. Osteoporos Int 14 suppl 5 (2003) S12-S15
14. Currey J. Role of collagen and other organics in the mechanical properties of bone. Osteoporos Int 14 suppl 5 (2003) S29-S36
15. Cooper C., Gehlbach S., and Lindsay R. Pathophysiology of osteoporosis. In: Cooper C., Gehlbach S., and Lindsay R. (Eds). Prevention and treatment of osteoporosis: a clinician's guide (2005), Taylor & Francis, London 27-42
16. Javaid M., and Cooper C. Prenatal and childhood influences on osteoporosis. Best Pract Res Clin Endocrinol Metab 16 (2002) 349-367
17. Naganathan V., MacGregor A., Snieder H., Nguyen T., Spector T., and Sambrook P. Gender differences in the genetic factors responsible for variation in bone density and ultrasound. J Bone Miner Res 17 (2002) 725-733
18. Bonjour J., Chevalley T., Ammann P., Slosman D., and Rizzoli R. Gain in bone mineral mass in prepubertal girls 3.5 years after discontinuation of calcium supplementation: a follow-up study. Lancet 358 (2001) 1208-1212
19. Ensrud K., Stone K., Cauley J., et al. Vitamin D receptor gene polymorphisms and the risk of fractures in older women. J Bone Miner Res 14 (1999) 1637-1645
20. Efstathiadou Z., Tsatsoulis A., and Ioannidis J. Association of collagen Ialpha 1 Sp1 polymorphism with the risk of prevalent fractures: a meta-analysis. J Bone Miner Res 16 (2001) 1586-1592
21. Mann V., Hobson E., Li B., et al. A COL1A1 Sp1 binding site polymorphism predisposes to osteoporotic fracture by affecting bone density and quality. J Clin Invest 107 (2001) 899-907
22. Pacifici R. Estrogen, cytokines and pathogenesis of postmenopausal osteoporosis. J Bone Miner Res 11 (1996) 1043-1051
23. Cenci S., Weitzmann M., Roggia C., et al. Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-α. J Clin Invest 106 (2000) 1229-1237
24. Pfeilschifter J., Koditz R., Pfohl M., and Schatz H. Changes in proinflammatory cytokine activity after menopause. Endocr Rev 23 (2002) 90-119
25. Hughes D., Dai A., Tiffee J., Li H., Mundy G., and Boyce B. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-β. Nat Med 2 (1996) 1131-1136
26. Boyle W., Scott Simonet W., and Lacey D. Osteoclast differentiation and activation. Nature 423 (2003) 337-342
27. Bord S., Ireland D., Beavan S., and Compston J. The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts. Bone 32 (2003) 136-141
28. Boyden L., Mao J., Belsky J., et al. High bone density due to a mutation in LDL-receptor related protein 5. N Engl J Med 346 (2002) 1513-1521
29. Little R., Carulli J., Del Mastro R., et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 70 (2002) 11-19
30. Gong Y., Slee R., Fukai N., et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107 (2001) 513-523
31. Koay M., Woon P., Zhang Y., et al. Influence of LRP5 polymorphisms on normal variation in BMD. J Bone Miner Res 19 (2004) 1619-1627
32. Bollerslev J., Wilson S., Dick I., et al. LRP5 gene polymorphisms predict bone mass and incident fractures in elderly Australian women. Bone 36 (2005) 599-606
33. Li X., Zhang Y., Kang H., et al. Sclerostin binds to LRP5/6 and antagonises canonical Wnt signalling. J Biol Chem 280 (2005) 19883-19887
34. Semenov M., Tamai K., and He X. SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem 280 (2005) 26770-26775
35. Loots G., Kneissel M., Keller H., et al. Genomic deletion of a long range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res 15 (2005) 928-935
36. Uitterlinden A., Arp P., Paeper B., et al. Polymorphisms in the sclerosteosis/van Buchem disease gene (SOST) region are associated with bone-mineral density in elderly white. Am J Hum Genet 75 (2004) 1032-1045
37. Marshall D., Johnell O., and Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312 (1996) 1254-1259
38. Kanis J., Borgstrom F., De Laet C., et al. Assessment of fracture risk. Osteoporos Int 16 (2005) 581-589
39. Garnero P., Sorney-Rendu E., Claustrat B., and Delmas P. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 15 (2000) 1526-1536
40. Johnell O., Oden A., de Laet C., Garnero P., Delmas P., and Kanis J. Biochemical indices of bone turnover and the assessment of fracture probability. Osteoporos Int 13 (2002) 523-526
41. Kannus P., Sievänen H., Palvanen M., Järvinen T., and Parkkari J. Prevention of falls and consequent injuries in elderly people. Lancet 366 (2005) 1885-1893
42. Parker M., Gillespie W., and Gillespie L. Hip protectors for preventing hip fractures in older people. Cochrane Database Syst Rev 3 (2005) CD001255
43. Reid I., Ames R., Evans M., Gamble G., and Sharpe S. Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: a randomized controlled trial. Am J Med 98 (1995) 331-335
44. Chapuy M., Arlot M., Duboeuf F., et al. Vitamin D3 and calcium to prevent hip fractures in the elderly. N Engl J Med 327 (1992) 1637-1642
45. Trivedi D., Doll R., and Khaw K. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ 326 (2003) 469-475
46. Grant A., Avenell A., Campbell M., et al. Randomised placebo-controlled trial of daily oral vitamin D3 and/or calcium for the secondary prevention of low trauma fractures in the elderly. Lancet 365 (2005) 1621-1628
47. Bischoff-Ferrari H., Willett W., Wong J., Giovannucci E., Dietrich T., and Dawson-Hughes B. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA 293 (2005) 2257-2264
48. Jackson R., LaCroix A., Gass M., et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 354 (2006) 669-683
49. Rossouw J., Anderson G., Prentice R., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 288 (2002) 321-330
50. Anderson G., Limacher M., Assaf A., et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291 (2004) 1701-1712
51. Salpeter S., Walsh J., Greyber E., Ormiston T., and Salpeter E. Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. J Gen Intern Med 19 (2004) 791-804
52. Cranney A., Guyatt G., Griffith L., et al. Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 23 (2002) 570-578
53. Black D., Cummings S., Karpf D., et al., for the Fracture Intervention Trial Research Group. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348 (1996) 1535-1541
54. Liberman U., Weiss S., Broll J., et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333 (1995) 1437-1443
55. Harris S., Watts N., Genant H., et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 282 (1999) 1344-1352
56. Reginster J., Minne H., Sorensen O., et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 11 (2000) 83-91
57. Chesnut C., Skag A., Christiansen C., et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19 (2004) 1241-1249
58. Storm T., Thamsborg G., Steiniche T., Genant H., and Sorenson O. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in postmenopausal osteoporosis. N Engl J Med 322 (1990) 1265-1271
59. Harris S., Watts N., Jackson R., et al. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis - three years of blinded therapy followed by one year of open therapy. Am J Med 95 (1993) 557-567
60. McClung M., Geusens P., Miller P., et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344 (2001) 333-340
61. Cummings S., Black D., Thompson D., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280 (1998) 2077-2082
62. Schnitzer T., Bone H., Crepaldi S., et al. Therapeutic equivalence of alendronate 70 mg once weekly and alendronate 10 mg in the treatment of osteoporosis. Aging Clin Exp Res 12 (2000) 1-12
63. Brown J., Kendler D., McClung M., et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tiss Int 71 (2002) 103-111
64. Johnell O., Scheele W., Lu Y., Reginster J., Need A., and Seeman E. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocr Metab 87 (2002) 985-992
65. Sambrook P., Geusens P., Ribot C., et al. Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International. J Intern Med 255 (2004) 503-511
66. Rosen C., Hochberg M., Bonnick S., et al. Treatment with once-weekly alendronate 70mg compared with once-weekly risedronate 35mg in women postmenopausal osteoporosis: a randomised double-blind study. J Bone Miner Res 20 (2005) 141-151
67. Kanis J., Oden A., Johnell O., et al. Uncertain future of trials in osteoporosis. Osteoporos Int 13 (2002) 443-449
68. Ensrud K., Barrett-Connor E., Schwartz A., et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. J Bone Miner Res 19 (2004) 1259-1269
69. Chavassieux P., Arlot M., Reda C., Wei L., Yates A., and Meunier P. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 100 (1997) 1475-1480
70. Sorensen O., Crawford G., Mulder H., et al. Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone 32 (2003) 120-126
71. Bone H., Hosking D., Devolelaer T., et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350 (2004) 1189-1199
72. Nancollas G., Tang R., Phipps R., et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 38 (2006) 628-636
73. Eastell R., Barton I., Hannon R., Chines A., Garnero P., and Delmas P. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18 (2003) 1051-1056
74. Caro J., Ishak K., Huybrechts K., Raggio G., and Naujoks C. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15 (2004) 1003-1008
75. Tosteson A., Grove M., Hammond C., et al. Early discontinuation of treatment for osteoporosis. Am J Med 115 (2003) 209-216
76. Miller P., McClung M., Macovei L., et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1 year results from the MOBILE study. J Bone Miner Res 20 (2005) 1315-1322
77. Reid I., Brown J., Burckhardt P., et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346 (2002) 653-661
78. Marx R. Pamidronate (Aredia) and zolendronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61 (2003) 1115-1117
79. Ruggiero S., Mehrotra B., Rosenberg T., and Engroff S. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62 (2004) 527-534
80. Delmas P., Bjarnason N., Mitlak B., et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337 (1997) 1641-1647
81. Ettinger B., Black D., Mitlak B., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 282 (1999) 637-645
82. Delmas P., Ensrud K., Adachi J., et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocr Metab 87 (2002) 3609-3617
83. Cranney A., Tugwell P., Zytaruk N., et al. Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. Endocr Rev 23 (2002) 524-528
84. Delmas P., Genant H., Crans G., et al. Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone 33 (2003) 522-532
85. Riggs B., and Melton L. Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density. J Bone Miner Res 17 (2002) 11-14
86. Siris E., Harris S., Eastell R., et al. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) Study. J Bone Miner Res 20 (2005) 1514-1524
87. Cummings S., Eckert S., Krueger K., et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281 (1999) 2189-2197
88. Chestnut C., Silverman S., Kim A., et al. A randomised trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence of Osteoporoitic Fractures study. Am J Med 109 (2000) 267-276
89. Cummings S. What PROOF proves about calcitonin and clinical trials. Am J Med 109 (2000) 330-331
90. Hodsman A., Bauer D., Dempster D., et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 26 (2005) 688-703
91. Neer R., Arnaud C., Zanchetta J., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344 (2001) 1434-1441
92. Cosman F., Nieves J., Zion M., Woelfert L., Luckey M., and Lindsay R. Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med 353 (2005) 566-575
93. Greenspan S., Bone H., Marriott T., et al. Preventing the first vertebral fracture in postmenopausal women with low bone mass using PTH (1-84): results from the TOP Study. J Bone Miner Res 20 suppl 1 (2005) S56
94. Ettinger B., San Martin J., Crans G., and Pavo I. Differential effects of teriparatide on bone mineral density after treatment with raloxifene or alendronate. J Bone Miner Res 19 (2004) 745-751
95. Black D., Bilezikian J., Ensrud K., et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 353 (2005) 555-565
96. Meunier P., Roux C., Seeman E., et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350 (2004) 459-468
97. Reginster J., Seeman E., De Vernejoul M., et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocr Metab 90 (2005) 2816-2822
98. McClung M., Lewiecki E., Cohen S., et al. Denusomab in postmenopausal women with low bone mineral density. N Engl J Med 354 (2006) 821-831